LEXINGTON, Mass.--(BUSINESS WIRE)--Sept. 11, 2006--NitroMed, Inc. (NASDAQ:NTMD) announced today that five poster presentations highlighting new findings related to BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride) will be presented at the 10th Annual Meeting of the Heart Failure Society of America (HFSA), being held at the Washington State Convention & Trade Center in Seattle, from September 10 - 13th. BiDil is currently marketed by NitroMed's sales force as adjunctive treatment for African Americans with heart failure. The drug was approved in June 2005 on the basis of outstanding clinical results from the Company's African American Heart Failure Trial (A-HeFT). Ongoing analyses of patient data from A-HeFT continue to provide valuable insight into how and in whom BiDil may provide treatment benefit.
